"Prodrugs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
| Descriptor ID |
D011355
|
| MeSH Number(s) |
D26.675
|
| Concept/Terms |
Prodrugs- Prodrugs
- Pro-Drugs
- Pro Drugs
- Drug Precursors
- Precursors, Drug
|
Below are MeSH descriptors whose meaning is more general than "Prodrugs".
Below are MeSH descriptors whose meaning is more specific than "Prodrugs".
This graph shows the total number of publications written about "Prodrugs" by people in this website by year, and whether "Prodrugs" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 2 | 3 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prodrugs" by people in Profiles.
-
An albumin-prodrug injectable formulation for synergistic cancer immunotherapy. J Colloid Interface Sci. 2025 May 15; 686:1019-1032.
-
Site-specific drug release of monomethyl fumarate to treat oxidative stress disorders. Nat Biotechnol. 2025 Oct; 43(10):1624-1627.
-
Self-Assembled Nanoparticles from the Amphiphilic Prodrug of Resiquimod for Improved Cancer Immunotherapy. ACS Appl Mater Interfaces. 2024 May 22; 16(20):25665-25675.
-
Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer. Prostate. 2024 Mar; 84(4):349-357.
-
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. J Nat Prod. 2020 04 24; 83(4):937-954.
-
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 01 31; 11(1):661.
-
Sustained delivery of a camptothecin prodrug - CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity. Int J Nanomedicine. 2019; 14:3799-3817.
-
Ultrahigh-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) assay for simultaneous quantifications of CZ48, lactone-stabilized camptothecin, and camptothecin and their pharmacokinetic and biliary evaluations in rats. J Pharm Biomed Anal. 2018 Nov 30; 161:122-128.
-
Scintillator-Based Nanohybrids with Sacrificial Electron Prodrug for Enhanced X-ray-Induced Photodynamic Therapy. Nano Lett. 2018 09 12; 18(9):5768-5774.
-
Adipocytes impair efficacy of antiretroviral therapy. Antiviral Res. 2018 06; 154:140-148.